Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

NCT04285827 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

CSL Behring